Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

Until about 20 years ago, people in the advanced stages of age-related macular degeneration ... approved a treatment for an advanced form of the disease known as wet AMD, in which new blood ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, ...

It is caused by abnormal blood vessel growth (a condition referred to as 'wet' macular degeneration) or atrophy and accumulation of debris ('dry' macular degeneration), both of which damage the ...

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

Without treatment ... can be treated with surgery, and wet AMD can be treated with medications and laser therapies. However, the most common form of macular degeneration, dry AMD, causes permanent ...

Myopic macular degeneration (MMD) is a serious eye condition that can cause vision loss that gets worse over time. Treatment may help reduce complications of MMD. Myopic macular degeneration (MMD ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.